This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Clovis Doubles on Buzz Over Lung Cancer Drug

Stocks in this article: CLVS BMRN TSRO

CHICAGO ( TheStreet) -- There's some confusion over the spark that's causing Clovis Oncology (CLVS) shares to double in value today. The company has presentations on two cancer drugs at the big American Society of Clinical Oncology (ASCO) annual meeting but it's the lung cancer drug -- CO-1686 -- which has set Wall Street heart fluttering.

J.P. Morgan analyst Cory Kasimov told clients this morning that the CO-1686 data were "extremely impressive."

In our first real look at Phase 1/2 efficacy data for the irreversible EGFRm inhibitor, the drug showed 4 confirmed partial responses (PRs) in heavily pre-treated T790M+ NSCLC pts, and they may not yet even be close to the maximum tolerated dose (MTD). In addition, 3/4 evaluable T790M+ patients treated at 900 mg BID (highest dose to date) achieved PRs. There were no clear investor expectations going in, but we strongly believe this is better than anyone's best case. Indeed, we see this as unprecedented activity in this patient population (and at what may still be a suboptimal dose). Emphasis Kasimov's.

Clovis shares are up $37.98, or 104%, to $74.56 in afternoon trading.

Clovis is also developing rucaparib, a PARP inhibitor. Phase I data in ovarian and breast cancer were presented at ASCO today. Biomarin (BMRN) and Tesaro (TSRO) have competing PARP inhibitors in clinical trials.

Rucaparib is playing a role in Clovis' big stock move today, but the real push is due to CO-1686 because there is no currently approved treatments for lung cancer patients with the T790M mutation.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs